Abstracts tagged "psoriatic arthritis and synovitis"

Abstract Number: 642 • 2017 ACR/ARHP Annual Meeting
Downstream Effects of Apremilast in Human Arthritic Ex Vivo Models
Tue Wenzel Kragstrup^1,2, Søren Lomholt², Morten Aagaard Nielsen², Line Dam Heftdal², Peter H. Schafer³ and Bent Deleuran^2,4, ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Department of Translational Development, Celgene Corporation, Summit, NJ, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Apremilast (Otezla) is a PDE4 inhibitor approved for the treatment of psoriasis and psoriatic arthritis, but the mechanisms of action of apremilast are not…
Abstract Number: 1578 • 2014 ACR/ARHP Annual Meeting
Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis – Preliminary Analysis from a Single Centre, Placebo-Controlled, Crossover Study
Agnes Szentpetery¹, Eric J. Heffernan², Muhammad Haroon³, Phil Gallagher¹, Anne-Marie Baker¹, Martina Cooney¹ and Oliver FitzGerald¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Radiology, St. Vincent's University Hospital, Dublin, Ireland, ³Newmarket On Fergus, Cork University Hospital, Cork, Ireland
Background/Purpose Abatacept is a soluble, fully human fusion protein which selectively inhibits T-cell activation via the CD80/CD86:CD28 co-stimulation pathway and decreases serum levels of inflammatory…
Abstract Number: 1183 • 2014 ACR/ARHP Annual Meeting
Validation of the Omeract Psoriatic Arthritis Magnetic Resonance Imaging Score for the Hand and Foot in a Randomized Placebo-Controlled Trial
Daniel Malm¹, P. Bird², Frédérique Gandjbakhch³, Philip J. Mease⁴, Pernille Bøyesen⁵, Mikkel Østergaard⁶, Charles G. Peterfy⁷ and Philip G. Conaghan⁸, ¹Center for Rheumatology and Spinal Diseases, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ²Combined Rheumatology Practice, Sydney, Australia, ³Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, Paris, France, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁷Spire Sciences LLC, Boca Raton, FL, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, United Kingdom
Background/Purpose The joint involvement in psoriatic arthritis (PsA) is heterogeneous, and inflammation is seen in both axial and peripheral joints, including the small joints of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].